Despite recent work suggesting that IL-33 may play an important fibrogenic role in IPF [11–19], the use of prophylactic dosing regimens in all previous studies means that the therapeutic benefit of targeting IL-33:ST2 signalling in IPF is poorly understood. Here, IL1RL1 is linked to idiopathic pulmonary fibrosis.